Abstract. Lung adenocarcinoma (LUAD) is one of the leading causes of cancer-related death worldwide. 14-3-3ơ is an intracellular phosphoserine-binding protein that has been proposed to be involved in tumorigenesis. However, the biofunctional role of 14-3-3ơ and its clinicopathological/prognostic significance in LUAD have remained elusive. In the present study, western blot and immunohistochemical analyses of cancer tissues/cells and the corresponding normal controls were performed to verify that 14-3-3ơ was upregulated in LUAD. Univariate and multivariate logistic regression analysis indicated that high expression of 14-3-3ơ predicted poor overall survival and progression-free survival of patients with LUAD. Furthermore, in vivo and in vitro experiments demonstrated that overexpression of 14-3-3ơ markedly promoted cell proliferation, colony formation, anchorage-independent growth and tumor growth, whereas 14-3-3ơ depletion produced the opposite effects. Of note, 14-3-3ơ was identified as an independent prognostic factor for patients with LUAD. Collectively, the present results revealed that high expression of 14-3-3ơ may serve as an independent biomarker, contributing to poor prognosis and progression of LUAD.

Introduction

Lung cancer, including non-small cell lung cancer (NSCLC) and SCLC, is one of the major causes of cancer-related death worldwide (1). NSCLC accounts for 80-85% of lung cancers and lung adenocarcinoma (LUAD) is the most prevalent sub-type of NSCLC (2). Difficulties in early diagnosis, high metastatic potential and the occurrence of treatment resistance in advanced disease are the reasons for the poor survival of patients with LUAD. Numerous targeted treatment drugs, such as gefitinib, erlotinib, and crizotinib, have been widely used in clinical treatment (3,4). Although molecularly targeted therapies have produced promising clinical outcomes, only a minority of patients with LUAD are ideal candidates for targeted therapies (5). Furthermore, curing patients with LUAD remains challenging due to target genetic resistance mutations or off-target mechanisms of resistance (6-8). Therefore, it is necessary to investigate more effective molecular pathological diagnosis and markers for predicting the prognosis of patients with LUAD.

The 14-3-3 protein family consists of at least seven isoforms, namely β, γ, ε, η, ξ, σ and τ/θ, which are present in mammalian cells (9). 14-3-3 proteins are involved in a variety of cell signal transduction processes, such as cell proliferation, cell cycle regulation, apoptosis and malignant transformation (10,11). In the 14-3-3 protein family, 14-3-3σ is most associated with tumor occurrence and development (12). 14-3-3ơ was originally identified as a human mammary epithelium marker 1 and as a tumor suppressor gene (13,14), which was determined to be reduced or lost in numerous types of solid tumor (15). Loss or reduction of 14-3-3ơ by CpG methylation or p53 mutation contributes to the progression of different types of carcinomas, including early stages of tumor development (16-21). This suggests that the function of 14-3-3ơ may help prevent the malignant transformation of epithelial cells. However, a growing body of evidence suggested that 14-3-3ơ does not act as a tumor suppressor in cancers. Enhanced 14-3-3ơ has been observed in pancreatic cancer (22), gastric carcinomas (23) and prostate cancer (24), and which is positively associated with aggressive tumor behavior and poor prognosis (15,25,26). Therefore, the biological role of 14-3-3ơ in tumorigenesis and progression of human cancers varies according to the specific tumor type.
In lung cancer, 14-3-3 protein was elevated in tumor tissues compared to normal tissues (9,27,28). Uprogelation of 14-3-3σ was also observed in LUAD (27) and NSCLC tissues (29). Increased expression of 14-3-3 may be due to the decreased DNA methylation of 14-3-3σ (30) and has been associated with cisplatin resistance in NSCLC cells (29). These results suggest that 14-3-3σ may be a promising biomarker for the molecular pathology, diagnosis and prognosis of patients with LUAD. However, only a small number of studies have reported on this possibility (29,31). Furthermore, the biological function of 14-3-3σ in tumorigenesis and progression of LUAD has remained to be fully elucidated. In the present study, the prognostic significance of 14-3-3σ in tumorigenesis and progression of LUAD was assessed by a bioinformatics analysis of the clinical features

Materials and methods

Cell lines and culture. The human bronchial epithelial immortalized cell line Beas-2B was purchased from the American Type Culture Collection and cultured in Bronchial Epithelial Basal Medium (BEBM; Lonza) with 10% fetal bovine serum (FBS; Corning, Inc.) and 1% penicillin/streptomycin (Gibco; Thermo Fisher Scientific, Inc.). The lung cancer cell lines NCI-H1299, NCI-H358, A-549 and NCI-H23 were purchased from Zhong Qiao Xin Zhou Biotechnology Co., Ltd. NCI-H1299, NCI-H358 and NCI-H23 were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS and 1% penicillin/streptomycin; A-549 was grown in F-12K medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS and 1% penicillin/streptomycin. All cells were maintained in a humidified incubator with 5% CO₂ at 37°C.

Clinical specimens. To detect the protein level of 14-3-3σ in LUAD tissue, a total of four LUAD tissue samples and non-tumor adjacent tissues samples were derived from biopsy samples and pathologically confirmed as LUAD from December 2020 to August 2021. Specific information on the patients is provided in Table I. The present study was performed according to the Declaration of Helsinki and approved by Ethics Committee of the People's Hospital of Beilun District (Ningbo, China; no. 2021-23(YS)). Each patient provided written informed consent prior to surgery.

To detect the relationship between 14-3-3σ and prognosis of patients with LUAD, a total of 106 paraffin-embedded LUAD specimens from the archives of the Department of Pathology at People's Hospital of Beilun (Ningbo, China) were included in the present study. All patients had undergone surgery from February 2002 to October 2003. All patients were pathologically confirmed as LUAD. Furthermore, they had no chemotherapy, radiation therapy or history of surgery. The patients, 66 males (62.3%) and 40 females (37.7%), ranged in age from 39 to 77 years (mean, 59 years). All patients received radical surgery for primary tumor and lymph nodes, and postoperative cisplatin-based adjuvant chemotherapy. The patients did not receive any radiotherapy or chemotherapy prior to surgery. The histological type and stage were determined according to the classification for NSCLC by the World Health Organization and the International Union against Cancer Tumor-Nodes-Metastasis staging system (32). All patients provided written informed consent for tissue use prior to surgery and this study was approved by the Institute Research Ethics Committee of People's Hospital of Beilun District (Ningbo, China). All patients had follow-up records for over 6 years. After the completion of therapy, patients were observed every 3 months for the first 3 years and every 6 months thereafter. Overall survival (OS) was defined as the time from diagnosis to the date of death, or at the latest date if patients were still alive. Progression-free survival (PFS) was determined from the first day of treatment to the earliest signs of disease progression as identified by CT or MRI, or death from any cause.

Plasmids, siRNA and transfection. Plasmids of HA-14-3-3σ were obtained from Professor Jie Xu from The Second Affiliated Hospital of the Third Military Medical University (Army Medical University, Chongqing, China). The targeting plasmids were delivered into NCI-H1299 LUAD cells using the Lipofectamine® 2000 transfection reagent (Cat No: 11668019; Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. siRNA designed to target 14-3-3σ was purchased from Sangon Biotech Co., Ltd., including si-14-3-3σ-18 (5'-GGAUCCACUCUUCUUGC A-3') and si-14-3-3σ-2# (5'-GACAUUGUAAUCUCUCAU U-3'). The sequence for the scrambled control siRNA was 5'-AUUGUGACUGCAUGCAGACU-3'. For transient transfection, control and si-14-3-3σ siRNA (#1 and #2) were mixed with Lipofectamine® 2000 and then added to the cell culture medium of A-549 LUAD cells according to the manufacturer's protocol. Finally, western blot analysis was used to assess the transfection efficiency.

ATP-lite cell proliferation assay. Cells were seeded into 96-well plates in triplicate at an initial density of 0.2x10⁴ cells/well. Cells were processed using the ATP-lite assay (cat. no. 6016739; Perkin-Elmer, Inc.) to assess cell proliferation at various time-points (24, 48, 72, 96 and 120 h) according to the manufacturer's protocol (33). Luminescence was read using a LD 400 plate reader (Beckman Coulter, Inc.). Each experiment was performed in triplicate.

Colony-formation assay. After transduction with targeting plasmids or small interfering (si)RNA, the stably transfected A-549 or NCI-H1299 cells were seeded into 6-cm dishes in triplicate at a density of 0.5x10⁵ cells/well and incubated at 37°C for 14 days. The colonies were fixed with 4% paraformaldehyde, stained with crystal violet and then counted (33).

Soft agar assay. A standard soft agar assay was done as detailed previously (34). In brief, 5x10³ of parental cells or their transfectants (14-3-3σ-overexpressing or 14-3-3σ silenced, along with the vector controls), were suspended in
ONCOLOGY LETTERS 24: 203, 2022

Table I. Clinicopathological data of the patients whose samples were used for western blot analysis.

| ID          | Sex | Age , years | Pathologic type                        | TNM stage |
|-------------|-----|-------------|----------------------------------------|-----------|
| 3397749     | Male| 51          | Infiltrating adenocarcinoma of the left upper lung | T1cN0M0   |
| 2296185     | Female| 41         | Infiltrating adenocarcinoma of the left upper lung | T1bN0M0   |
| 2295463     | Male| 43          | Infiltrating adenocarcinoma of the left upper lung | T1bN0M0   |
| 2287639     | Male| 41          | Infiltrating adenocarcinoma of the right upper lung | T1cN0M0   |

Western blot analysis. Total protein was extracted from cells using RIPA lysis buffer (50 mM Tris-pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS; cat. no. P0013B; Beyotime Institute of Biotechnology) supplemented with phosphatase (cat. no. B15001; Bimake) and protease inhibitors (cat. no. BI4001; Bimake). BCA assay kit (cat. no. P0011; Beyotime Institute of Biotechnology) was used to determine the protein concentration and 40 µg protein was loaded onto the gel per lane. The equal amounts of total protein were separated by SDS-PAGE (8-15%) and then transferred onto nitrocellulose (NC) membranes (EMD Millipore). The NC membranes were blocked with 5% nonfat milk (cat. no. P0216; Beyotime Institute of Biotechnology) for 1 h at room temperature, followed by incubation with primary antibodies overnight at 4°C. The following primary antibodies were used: 14-3-3σ (cat. no. sc-100638; 1:1,000 dilution; Santa Cruz Biotechnology, Inc.), poly (ADP-ribose) polymerase (PARP; cat. no. 13371-1-AP; 1:1,000 dilution; Santa Cruz Biotechnology, Inc.), Caspase-3 (cat. no. 66470-2-Ig; 1:1,000 dilution; ProteinTech Group, Inc.), GAPDH (cat. no. 60004-1-Ig; 1:1,000 dilution; ProteinTech Group, Inc.) and hemagglutinin (HA)-tag (cat. no. SA1064-2-AP; 1:1,000 dilution; ProteinTech Group, Inc.). The NC membranes were then incubated with the following corresponding secondary antibodies: Goat anti-rabbit IgG (cat. no. SA0001-1; 1:2,000 dilution; ProteinTech Group, Inc.); goat anti-mouse IgG (cat. no. SA0001-1; 1:2,000 dilution; ProteinTech Group, Inc.); goat anti-rat IgG (cat. no. SA0001-15; 1:2,000 dilution; ProteinTech Group, Inc.) for 1 h at room temperature. ECL reagent (cat. no. 32106; Thermo Fisher Scientific, Inc.) was used to detect the signals.

Selection of cutoff score for 14-3-3σ expression. A receiver operating characteristic (ROC) curve analysis was performed for the selection of the cutoff value of the 14-3-3σ IHC score for OS and PFS, as described previously (36). In brief, the sensitivity and specificity of the outcome being studied for each score were plotted to generate an ROC curve. The score localized closest to the point of maximum sensitivity and specificity, the point on the curve (0.0, 1.0), was selected as the cutoff score leading to the highest number of tumors correctly classified as with or without the respective outcome. To facilitate the ROC curve analysis, the patients' outcome characteristics were dichotomized by survival [death vs. other outcome (censored, alive or death from other causes)].

Animal experiment. All experimental procedures using mice were performed in accordance with protocols approved by the Laboratory Animal Welfare and Ethics Committee of The Third People's Hospital of Yunnan Province (Kunming, China). A total of eight BALB/C nude mice (nu/nu; male; aged, 4-6 weeks; body weight, 18-20 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and each experimental group consisted of four mice. In brief, 5×10^5 NCI-H1299 cells stably transfected with Vector or HA-14-3-3σ were mixed 1:1 with Matrigel® in a total volume of 0.2 ml and injected subcutaneously into the right flank of each mouse (37). Tumor size and mouse body weight were measured twice a week with a vernier caliper and precise analytical balance, respectively. On day 28 after tumor cell injection, mice were euthanized by carbon dioxide asphyxiation (30% vol/min) when certain tumors reached the size limits set by the guidelines ‘Tumor Induction in Mice and Rats-UCSF Animal Care and Use’ (38). The largest sizes of

Immunohistochemical (IHC) analysis and scoring. IHC analysis was used to study 14-3-3σ protein expression in human LUAD tissues and normal adjacent tissues as controls. The slides were dewaxed in xylene, rehydrated with an alcohol gradient, immersed in 3% hydrogen peroxide for 10 min to block endogenous peroxidase activity and subjected to antigen retrieval by pressure cooking in Tris/EDTA (pH=8.0) for 10 min. The slides were then incubated with 14-3-3σ primary antibody overnight at 4°C. After incubation with the secondary antibody for 30 min at 37°C, the specimens were stained with a DAB staining kit (cat. no. ab64238; Abcam). Finally, the sections were counterstained with hematoxylin, dehydrated and fixed. The brown granules in the cytoplasm were considered as positive staining for 14-3-3σ. For the evaluation of nuclear and cytoplasmic staining, the staining intensity was scored as follows (35): Negative (score 0); weak (score 1); moderate (score 2) and strong (score 3). The degree of staining was divided into four categories according to the percentage of stained cells in the field: Negative (score 0%), 0-25% (score 1), 26-75% (score 2), 56-100% (score 3) and 76-100% (score 4). The results reported as the expression score were the product of the above two scores. Protein expression was then evaluated by jointly assessing the intensity and extent of staining. IHC staining was assessed and scored by two independent researchers (JL and CDZ), who were blinded to the clinicopathological data.
tumor in the study were no bigger than 16 mm. At 10 min after the animals were euthanized by carbon dioxide asphyxiation, the absence of vital signs was checked to confirm that the animals had died. In this study, the nude mice did not suddenly lose 20‑25% weight (cachexia); therefore, no other humane endpoint was used in this experiment except for tumor size limitation. Tumors were excised, weighed and frozen or fixed in 4% paraformaldehyde and paraffin‑embedded for IHC analysis. The mean tumor volume (TV) was calculated according to the following equation: TV=(L x W^2)/2, where L is the length and W is the width of the tumor.

IHC staining of mouse tumors was performed as described above. In brief, after deparaffinization, rehydration, antigen retrieval and blocking, the tissue slides were incubated overnight at 4°C with the indicated antibodies. The following primary antibodies were used: Ki‑67 (1:1,000 dilution; cat. no. 9449; Cell Signaling Technology, Inc.), p21 (1:200 dilution; cat. no. 10355‑1‑AP; ProteinTech Group, Inc.), p27 (1:200 dilution; cat. no. 25614‑1‑AP; ProteinTech Group, Inc.) and cleaved‑Caspase‑3 (Asp175) (1:200 dilution; cat. no. 9664; Cell Signaling Technology, Inc.).

Statistical analysis. All data were expressed as the mean ± standard deviation and statistical charts were prepared using GraphPad Prism 7.0 software (GraphPad Software, Inc.) and SPSS 20.0 (IBM Corporation). Transcripts per million (TPM) values were used and survival analysis was applied for assessing differential expression of 14‑3‑3σ mRNA levels in UALCAN. For survival analysis, the χ^2 test or Fisher’s exact test was used to assess the association...
between 14-3-3σ protein expression and clinicopathological variables. The multivariate Cox proportional hazards model was used to estimate the hazard ratios and 95% confidence intervals for patient outcomes. The associations between 14-3-3σ protein expression and OS or PFS were determined by Kaplan-Meier analysis. The log-rank test was performed...
to assess differences in survival probability between patient subsets. Differences between two groups were analyzed using an unpaired Student’s t-test, while the expression of 14-3-3σ in tumor tissues and matched normal tissues was compared using a paired Student’s t-test. Comparisons of multiple groups were performed using one-way ANOVA followed by Dunnett’s or Tukey’s test. *P*<0.05 was considered to indicate a statistically significant difference.

**Results**

*Integrated analysis indicates that 14-3-3σ is an oncogene in LUAD.* It was previously reported that 14-3-3σ expression is present in LUAD (27), but the biofunction role of 14-3-3σ and its clinicopathological/prognostic significance in LUAD have remained elusive. In the present study, 14-3-3σ mRNA expression was analyzed in LUAD using the data from UALCAN (http://ualcan.path.uab.edu/). Significant differences were identified between LUAD tissues and their normal counterparts (Fig. 1A). For the dataset from UALCAN, Kaplan-Meier survival analysis also indicated that patients with higher 14-3-3σ mRNA expression had poor overall survival (Fig. 1B). Next, the protein expression of 14-3-3σ was examined in LUAD and adjacent normal tissues by western blot analysis (Fig. 1C), and it was observed that 14-3-3σ was upregulated in LUAD tissues, whereas its expression was low in the normal adjacent tissue. Consistent with this result, the expression of 14-3-3σ in four established LUAD cell lines (A-549, NCI-H1299, NCI-H358 and NCI-H23) and a human bronchial epithelial cell line (Beas-2B) was analyzed by western blot analysis, indicating that 14-3-3σ was highly expressed in LUAD cell lines (Fig. 1D). Taken together, 14-3-3σ may function as an oncogene for LUAD.

**14-3-3σ expression and survival: Univariate analysis.** Consistent with the western blot results, IHC analysis revealed that 14-3-3σ was present in the cytoplasm and highly expressed in LUAD tissues (Fig. 2Aa and a2), while it was weakly expressed in normal paired lung tissues (Fig. 2Ac and c2). Next, ROC curve analysis was employed to determine a cutoff score for 14-3-3σ expression to predict survival (Fig. 2B). The cutoff score for 14-3-3σ to predict OS and PFS in patients with LUAD (n=106) was 3.8 (*P*<0.001) and 4.1 (*P*=0.017), respectively. Therefore, a 14-3-3σ expression score of 4.0 (>4.0 vs. ≤4.0) was selected as the unified cutoff point for survival analysis in patients with LUAD. The ROC-derived 14-3-3σ cutoff score for patients with LUAD was 4 and the cohort (n=106) was divided into a high (52/106, 49.1%) and a low (54/106, 50.9%) expression group. Kaplan-Meier analysis further indicated that high expression of 14-3-3σ predicted an inferior OS and PFS in patients with LUAD (*P*<0.001, Fig. 2C).

**14-3-3σ expression in LUAD tissues and clinical features of patients.** The association between 14-3-3σ expression and the clinical characteristics of patients with LUAD was then examined. As presented in Table II, high expression of 14-3-3σ in LUAD tissues was significantly positively associated with the tumor stage (*P*=0.001). In addition, high expression of 14-3-3σ was associated with tumor size (*P*=0.036) and recurrence (*P*<0.001, Table II). However, no association between 14-3-3σ overexpression and other patient characteristics was observed, including patient age, sex or node stage.

| Variable          | Total n | High  | Low  | P-value |
|-------------------|---------|-------|------|---------|
| Age, years        |         |       |      |         |
| ≥59.00            | 56      | 32    | 24   | 0.078   |
| <59.00            | 50      | 20    | 30   |         |
| Sex               |         |       |      | 0.803   |
| Male              | 66      | 33    | 33   |         |
| Female            | 40      | 19    | 21   |         |
| Tumor size (mm)   |         |       |      | 0.036   |
| <20               | 7       | 5     | 6    |         |
| 20-50             | 53      | 18    | 31   |         |
| >50               | 46      | 29    | 17   |         |
| Tumor stage       |         |       |      | 0.001   |
| T1+T2             | 52      | 17    | 35   |         |
| T3+T4             | 54      | 35    | 19   |         |
| Node stage        |         |       |      | 0.227   |
| N0+N1             | 45      | 19    | 26   |         |
| N2+N3             | 61      | 33    | 28   |         |
| Recurrence        |         |       |      | <0.001  |
| Positive          | 61      | 46    | 15   |         |
| Negative          | 45      | 6     | 39   |         |

*Multivariate Cox regression analysis.* To avoid the influence of various factors in the univariate analysis, the expression of 14-3-3σ as well as other parameters were examined in a multivariate Cox regression analysis (Table III). Among the patients with LUAD, 14-3-3σ was indeed determined to be a significant independent prognostic factor for OS (hazard ratio, 4.878; 95% CI, 2.895-8.219; *P*<0.001; Table III) and PFS (hazard ratio, 3.041; 95% CI, 1.878-4.923; *P*<0.001; Table III). Furthermore, the node stage was also identified as an independent prognostic parameter for OS (hazard ratio, 2.396; 95% CI, 1.155-5.48; *P*=0.025; Table III) and PFS (hazard ratio, 2.471; 95% CI, 1.168-5.228; *P*=0.018; Table III) in the patients with LUAD. However, other important prognostic factors, including age, sex, smoking, tumor stage and metastasis, were no significant independent prognostic factors for LUAD according to this analysis, implying that a larger cohort may be required in future studies.

**14-3-3σ overexpression promotes growth of LUAD cells in vitro.** The above results suggested that high expression of 14-3-3σ was associated with progression and poor prognosis of LUAD. Thus, the biological function of 14-3-3σ in LUAD was further investigated in vitro. First, 14-3-3σ plasmid was transfected into NCI-H1299 LUAD cells (Fig. 3A), as the native cell line expressed 14-3-3σ at a low level (Fig. 1D), and it was indicated that overexpression of 14-3-3σ promoted cell
Table III. Results of multivariate Cox proportional hazards analysis in lung adenocarcinoma.

| Variable | Hazard ratio (95% confidence interval) | P-value | Hazard ratio (95% confidence interval) | P-value |
|----------|---------------------------------------|---------|---------------------------------------|---------|
| Age (≥59.00 vs. <59 years) | 1.390 (0.888-2.176) | 0.150 | 1.168 (0.749-1.822) | 0.492 |
| Sex (male vs. female) | 0.624 (0.301-1.292) | 0.204 | 0.869 (0.407-1.858) | 0.718 |
| Smoking (yes vs. no) | 0.939 (0.468-1.883) | 0.859 | 1.052 (0.510-2.168) | 0.892 |
| Tumor size, mm | | | | |
| <20 | 1.024 (0.357-2.937) | 0.965 | 0.781 (0.275-2.218) | 0.642 |
| 20-50 | 1.287 (0.758-2.185) | 0.351 | 1.153 (0.679-1.958) | 0.598 |
| >50 | 1.130 (0.667-1.915) | 0.649 | 1.307 (0.777-2.201) | 0.313 |
| Tumor stage (T4 + T3 vs. T2 + T1) | | | | |
| Nodal stage (N3 + N2 vs. N1 + N0) | 2.396 (1.115-5.148) | 0.025 | 2.471 (1.168-5.228) | 0.018 |
| 14-3-3ơ (high vs. low) | 4.878 (2.895-8.219) | <0.001 | 3.041 (1.878-4.923) | <0.001 |

Discussion

LUAD is one of the most common causes of global cancer-related mortalities worldwide (39). Although previous studies have indicated that numerous abnormally expressed genes in LUAD may help classify prognostic risks (40-42), there is still an urgent requirement for novel molecular markers to identify tumor progression and predict prognosis. The 14-3-3 family of proteins has received considerable attention in the past few years due to their involvement in cancers by regulating a variety of cellular processes (10,11). 14-3-3ơ was originally identified as a tumor suppressor gene (13-15), which was upregulated by p53 upon DNA damage, and reported to sequester the essential mitosis initiation complex cdc2-cyclin B1 into the nucleus, thus preventing the initiation of mitosis (42-45). As a result, 14-3-3ơ induces G2 arrest, allowing DNA damage repair to take place (18-20). However, there is increasing evidence that 14-3-3ơ is an oncogene in cancers (22-24). Although 14-3-3ơ expression was observed in LUAD (27), its significance for the following was provided: i) 14-3-3ơ is strongly expressed in both LUAD cells and tissues. Similar to the findings in previous studies (27); ii) overexpression of 14-3-3ơ significantly promotes cell growth and survival in both in vitro and in vivo LUAD cancer models, whereas 14-3-3ơ depletion produces opposite effects; iii) 14-3-3ơ depletion also induces cell apoptosis, as evidenced by the increase of PARP cleavage and Caspase-3 cleavage; iv) high expression of 14-3-3ơ positively correlates with tumor size, tumor stage and recurrence, worse OS and PFS in LUAD; v) multivariate analyses further...
revealed that 14-3-3σ is an independent prognostic biomarker for patients with LUAD. Taken together, the findings of the present study provided evidence that overexpression of 14-3-3σ may contribute to an increased degree of malignancy and unfavorable prognostic phenotype in LUAD.

Data reported by certain studies are completely contradictory regarding the prognostic impact of 14-3-3σ in different human cancers. Loss of expression of 14-3-3σ has been documented to be associated with poor prognosis in patients with breast cancer (46,47), endometrial (48) and ovarian cancers (49). However, consistent with findings in pancreatic cancer (50) and colorectal cancer (51), the results of the present study suggested that high expression of 14-3-3σ was positively associated with poor survival. The underlying mechanism(s) by which 14-3-3σ affected cancer prognosis may depend on the intrinsic properties of the tumor type. More recently, studies have indicated that overexpression of 14-3-3σ is associated with tumor progression in pancreatic cancer (26,50), which may further explain the present findings that higher 14-3-3σ expression was predominantly detected in more advanced tumor stages.

In conclusion, in the present study, 14-3-3σ was identified as an independent prognostic biomarker for OS and PFS in LUAD. The results suggested that 14-3-3σ has clinical value in predicting the prognosis of LUAD and identifying patients with LUAD at high risk of progression and recurrence.
Although the present study reported the effects of 14-3-3σ in LUAD, the regulatory mechanisms remain to be elucidated. In the future, further research will be performed to investigate how 14-3-3σ regulates cellular processes in LUAD.
Acknowledgements

The authors would like to thank Professor Jie Xu (The Second Affiliated Hospital of the Third Military Medical University, Army Medical University, Chongqing, China) for providing cell lines, plasmids and research cooperation.

Figure 5. Overexpression of 14-3-3σ promotes LUAD tumor growth in vivo. (A-C) Overexpression of 14-3-3σ promoted tumor growth in vivo xenograft LUAD models. NCI-H1299 cells stably expressing HA-14-3-3σ or transfected with vector were subcutaneously inoculated in the right flank of nude mice. After the indicated times, the tumors were harvested, (A) images were captured and (B) their weight was determined. (C) The tumor growth was measured and plotted. (D) Immunohistochemical staining of xenograft tumor tissues. Tumor tissues from two groups of nude mice were fixed, sectioned and stained with indicated antibodies (scale bars, 100 µm). Values are expressed as the mean ± standard error of the mean (n=4). ns, no significance; *P<0.05; **P<0.01; ***P<0.001; paired or unpaired two-tailed Student's t-test. LUAD, lung adenocarcinoma.

Funding

This work was supported by the National Natural Science Foundation of China (grant no. 81860017 to HFL) and Yunnan Provincial Department of Education Science Research Fund Project (grant no. 2019J0792 to JL).
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Author's contributions

HFL and YBC were involved in the conception and design of the research. HFL edited and revised the manuscript. JFF, JL and CDZ performed the experiments, interpreted the results of the experiments and prepared the figures. YBC and JG drafted the manuscript. JG was also responsible for the collection of clinical data. HFL and YBC confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The protocol for the study involving human participants was reviewed and approved by the Ethics Committee of the People's Hospital of Beilun District of China [Ningbo, China; no. 2021-23(YS)]. The patients/participants provided their written informed consent to participate in this study. The animal experiment was approved by the Institutional Animal Care and Use Committee of the People's Hospital of Beilun District of China (Ningbo, China; no. NBU20220098).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Robinson KW and Sandler AB: The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist 18: 115-122, 2013.
3. Kobayashi Y and Mitsudomi T: Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci 107: 1179-1186, 2016.
4. Karachaliou N, Santarpia M, Cao MZ, Teixido C, Sosa AE, Berenguer J, Capote AR, Altavilla G and Rosell R: Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. Expert Opin Investig Drugs 26: 713-722, 2017.
5. Roviello G: The distinctive nature of adenocarcinoma of the lung. Onco Targets Ther 8: 2399-2406, 2015.
6. Sacco JJ, Al-Akrass H and Wilson CM: Challenges and strategies in precision medicine for non-small-cell lung cancer. Curr Pharm Des 22: 4374-4385, 2016.
7. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dugogo-Jack I, Gudgel S, Schultz K, Singh M, et al.: Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6: 1118-1133, 2016.
8. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meverson M, Johnson BE, Eick MJ, Tenen DG and Haimos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005.
9. Raungrut P, Wongkotsila A, Lirdprapamongkol K, Svasti J, Geater SL, Phukouloun M, Suwiat S and Thongsuksai P: Prognostic significance of 14-3-3sigma overexpression in non-small cell lung cancer. Asian Pac J Cancer Prev 15: 3513-3518, 2014.
10. Porter GW, Khuri FR and Fu H: Dynamic 14-3-3-client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol 16: 193-202, 2006.
11. Morrison DK: The 14-3-3 proteins: Integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 19: 16-23, 2009.
12. Huang Y, Yang M and Huang W: 14-3-3 σa: A potential biomolecule for cancer therapy, Clin Chim Acta 511: 50-58, 2020.
13. Ling C, Zuo D, Xue B, Muthuswamy S and Muller WJ: A novel role for 14-3-3sigma in regulating epithelial cell polarity. Genes Dev 24: 947-956, 2010.
14. Ling C, Su VM, Zuo D and Muller WJ: Loss of the 14-3-3sigma tumor suppressor is a critical event in ErbB2-mediated tumor progression. Cancer Discov 2: 68-81, 2012.
15. Boudreau A, Tanner K, Wang D, Geyer FC, Reis-Filho JS and Bissell MJ: 14-3-3sigma stabilizes a complex of soluble actin and intermediate filament to enable breast tumor invasion. Proc Natl Acad Sci USA 110: E3937-E3944, 2013.
16. Lodigyn D and Hermeking H: The role of epigenetic inactivation of 14-3-3sigma in human cancer. Cell Res 15: 237-246, 2005.
17. Nacht M, Ferguson AT, Zhang W, Petrozziello JM, Cook BP, Gao YH, Maguire S, Riley D, Coppola G, Landes GM, et al.: Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 59: 5464-5470, 1999.
18. Boucheron AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futeal PA, Stumper MR and Sukumar S: High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 97: 6049-6054, 2000.
19. Lodigyn D, Diebold J and Hermeking H: Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression. Oncogene 23: 9034-9041, 2004.
20. Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, Kaneto H, Iku S, Ozeki I, Karino Y, et al.: Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 19: 5298-5302, 2000.
21. Lodigyn D, Epanchintsev A, Menssen A, Diebold J and Hermeking H: Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 65: 4218-4227, 2005.
22. Okuda T, Masuda N, Fukai Y, Shimura T, Nishida Y, Hosouchi Y, Kashiwabara K, Nakajima T and Kuwano H: Immunohistochemical expression of 14-3-3 sigma protein in intraductal papillary-mucinous tumor and invasive ductal carcinoma of the pancreas. Anticancer Res 26(4B): 3105-3110, 2006.
23. Kuramitsu Y, Baron B, Yoshino S, Zhang X, Tanaka T, Yashiro M, Hirakawa K, Oka M and Nakamura K: Proteomic differential display analysis shows up-regulation of 14-3-3 sigma protein in human scirrhous-type gastric carcinoma cells. Anticancer Res 30: 4459-4465, 2010.
24. Ito Y, Miyoshi E, Uda E, Yoshida H, Uruso T, Takamura Y, Miya A, Kobayashi K, Matsuoka F, Matsuura N, et al.: 14-3-3 sigma possibly plays a constitutive role in papillary carcinoma, but not in follicular tumor of the thyroid. Cancer Lett 200: 161-166, 2003.
25. Neal CL and Yu D: 14-3-3; as a prognostic marker and therapeutic target for cancer. Expert Opin Ther Targets 14: 1334-1350, 2010.
26. Guwiedhi A, Kleeff J, Giese N, El Fitori J, Ketterer K, Giese T, Büchler MW, Kore M and Friess H: Enhanced expression of 14-3-3 sigma protein in human scirrhous-type gastric carcinoma cells. Anticancer Res 30: 4459-4465, 2010.
30. Radhakrishnan VM, Jensen TJ, Cui H, Futscher BW and Martinez JD: Hypomethylation of the 14-3-3sigma promoter leads to increased expression in non-small cell lung cancer. Genes Chromosomes Cancer 50: 830-836, 2011.

31. Wang R, Yan B, Li Z, Jiang Y, Mao C, Wang X and Zhou X: Long non-coding RNA HOX transcript antisense RNA promotes expression of 14-3-3sigma in non-small cell lung cancer. Exp Ther Med 14: 4503-4508, 2017.

32. Carbone L: Pain management standards in the eighth edition of the guide for the care and use of laboratory animals. J Am Assoc Lab Anim Sci 51: 322-328, 2012.

33. Xu J, Zhou W, Yang F, Chen G, Li H, Zhao Y, Liu P, Li H, Tan M, Xiong X and Sun Y: The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. Nat Commun 8: 14002, 2017.

34. Gu Q, Tan M and Sun Y: SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetate-induced neoplastic transformation. Cancer Res 67: 3616-3625, 2007.

35. Wang B, Liang X, Li S, Li T, Zheng L, Shao W, Wang Y, Liu F, Ma L and Jia J: Orphan nuclear receptor Nurr1 promotes Helicobacter pylori-associated gastric carcinogenesis by directly enhancing CDK4 expression. EBioMedicine 53: 102672, 2020.

36. Zhou WH, Tang F, Xu J, Wu X, Yang SB, Feng ZY, Ding YG, Wan XB, Guan Z, Li HG, et al: Low expression of Beclin 1, associated with high Bel-5XL, predicts a malignant phenotype and poor prognosis of gastric cancer. Autophagy 8: 389-400, 2012.

37. Zhou W, Xu J, Tan M, Li H, Li H, Wei W and Sun Y: UBE2M is a stress-inducible dual E2 for neddylation and ubiquitylation that promotes targeted degradation of UBE2F. Mol Cell 70: 1008-1024, 2018.

38. Travis WD, Brambilla E, Burke AP, Marx A and Nicholson AG: Introduction to The 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 10: 1240-1242, 2015.

39. Zhang Y, Yuan Y, Li Y, Zhang P, Chen P and Sun S: An inverse interaction between HOXA11 and HOXA11-AS is associated with cisplatin resistance in lung adenocarcinoma. Epigenetics 14: 949-960, 2019.

40. Jin CY, Du L, Nuerlan AH, Wang XL, Yang YW and Guo R: High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging (Albany NY) 13: 3518-3535, 2020.

41. Yu Y and Tian X: Analysis of genes associated with prognosis of lung adenocarcinoma based on GEO and TCGA databases. Medicine (Baltimore) 99: e20183, 2020.

42. Zhang Y, Liu X, Liu L, Li J, Hu Q and Sun R: Expression and prognostic significance of m6A-related genes in lung adenocarcinoma. Med Sci Monit 26: e919644, 2020.

43. Dellinger RW, Karjian PL and Neuteboom ST: NB1011 induces Ser15 phosphorylation of p53 and activates the G2/M checkpoint. Anticancer Drugs 14: 449-455, 2003.

44. Holm R, Ali T, Svendsrud DH, Nesland JM, Kristensen GB and Lyng H: Expression of 14-3-3sigma in cervical squamous cell carcinomas: Relationship with clinical outcome. Oncol Rep 22: 11-15, 2009.

45. Horie-Inoue K and Inoue S: Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers. Semin Cancer Biol 16: 235-239, 2006.

46. Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Steele D, Cossu A, Budroni M, Palmieri G and Lakhani SR: Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol 202: 274-285, 2004.

47. Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensr J, et al: 14-3-3sigma overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 69: 3425-3432, 2009.

48. Nakayama H, Sano T, Motegi A, Oyama T and Nakajima T: Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma. Pathol Int 55: 707-715, 2005.

49. Akahira J, Sugihashi Y, Suzuki T, Ito K, Niikura H, Moriya T, Nitta M, Okamura H, Inoue S, Sasano H, et al: Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: Its correlation with aberrant DNA methylation. Clin Cancer Res 10: 2687-2693, 2004.

50. Li Z, Dong Z, Myer D, Yip-Schneider M, Liu J, Cui P, Schmidt CM and Zhang JT: Role of 14-3-3sigma in poor prognosis and in radiation and drug resistance of human pancreatic cancers. BMC Cancer 10: 274-285, 2010.

51. Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, Margreiter R andamberger A: 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 11: 3274-3279, 2005.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.